Research Progress on the Correlation between DKK3 and Cervical Cancer

doi:10.12280/gjfckx.20210129

Abstract

Abstract:

Cervical cancer is a common gynecological malignant tumor with high morbidity and mortality. DKK3 (dickkopf-3) is an antagonist of the classic Wnt signaling pathway and a tumor suppressor gene discovered in recent years. DKK3 exerts its anti-tumor function by regulating β-catenin signal transduction pathway, reversing epithelial-mesenchymal transition, inhibiting tumor angiogenesis and other pathways. It is a potential target in tumor therapy. Epigenetic modification of genes, especially promoter methylation, plays a very important role in the occurrence and development of a variety of malignant tumors. Hypermethylation in the promoter region of DKK3 gene is an important reason for the inactivation of DKK3 protein, which makes the Wnt signaling pathway abnormally activated, leading to the occurrence of tumors. The expression of DKK3 is often down-regulated in cervical cancer tissues, and the silencing of DKK3 expression caused by the methylation of the gene promoter is a frequent event in cervical cancer. The methylation level and expression level of DKK3 are significantly correlated to the prognosis of patients with cervical cancer, and it has a good predictive effect. Therefore, in-depth study on the relationship between DKK3 and cervical cancer may provide new ideas for the mechanism research, targeted therapy and prognosis judgment of cervical cancer.

Key words: Dickkopf-3, Uterine cervical neoplasms, Genes,tumor suppressor, Methylation, Wnt signaling pathway

ZHANG Shao-fen, WANG Zhi-lian. Research Progress on the Correlation between DKK3 and Cervical Cancer[J]. Journal of International Obstetrics and Gynecology, 2021, 48(6): 624-627.

References 28

[1]	王艳清, 杨潇, 鲜舒, 等. DNA甲基化与卵巢癌耐药关系的研究进展[J]. 国际妇产科学杂志, 2018,45(6):616-620. doi: 10.3969/j.issn.1674-1870.2018.06.003. doi: 10.3969/j.issn.1674-1870.2018.06.003
[2]	Niehrs C. Function and biological roles of the Dickkopf family of Wnt modulators[J]. Oncogene, 2006,25(57):7469-7481. doi: 10.1038/sj.onc.1210054. doi: 10.1038/sj.onc.1210054 pmid: 17143291
[3]	Krupnik VE, Sharp JD, Jiang C, et al. Functional and structural diversity of the human Dickkopf gene family[J]. Gene, 1999,238(2):301-313. doi: 10.1016/s0378-1119(99)00365-0. doi: 10.1016/s0378-1119(99)00365-0 pmid: 10570958
[4]	李铭, 王玲, 王一男, 等. 宫颈腺癌中抑癌基因甲基化的研究进展[J]. 国际妇产科学杂志, 2020,47(6):611-615. doi: 10.3969/j.issn.1674-1870.2020.06.002. doi: 10.3969/j.issn.1674-1870.2020.06.002
[5]	Fujii Y, Hoshino T, Kumon H. Molecular simulation analysis of the structure complex of C2 domains of DKK family members and β-propeller domains of LRP5/6: explaining why DKK3 does not bind to LRP5/6[J]. Acta Med Okayama, 2014,68(2):63-78. doi: 10.18926/AMO/52403. doi: 10.18926/AMO/52403
[6]	Leonard JL, Leonard DM, Wolfe SA, et al. The Dkk3 gene encodes a vital intracellular regulator of cell proliferation[J]. PLoS One, 2017,12(7):e0181724. doi: 10.1371/journal.pone.0181724. doi: 10.1371/journal.pone.0181724
[7]	Lee EJ, Nguyen Q, Lee M. Dickkopf-3 in Human Malignant Tumours: A Clinical Viewpoint[J]. Anticancer Res, 2020,40(11):5969-5979. doi: 10.21873/anticanres.14617. doi: 10.21873/anticanres.14617
[8]	Nie XC, He F, Lan C, et al. Combined Serum DKK3 and Circulating CD133 Cells as Prognostic Biomarkers for Ovarian Cancer Patients[J]. Onco Targets Ther, 2021,14:427-434. doi: 10.2147/OTT.S288191. doi: 10.2147/OTT.S288191
[9]	陈曦, 孙延芳, WINSTON Nxumalo. Dickkopfs分泌蛋白调控肿瘤细胞机制[J]. 浙江理工大学学报(自然科学版), 2020,43(2):253-261.
[10]	Mohammadpour H, Pourfathollah AA, Nikougoftar Zarif M, et al. Effects of DKK-3, a Wnt signaling inhibitor, on dendritic cell phenotype and T cell polarization[J]. Immunopharmacol Immunotoxicol, 2015,37(6):481-487. doi: 10.3109/08923973.2015.1089274. doi: 10.3109/08923973.2015.1089274
[11]	Kinoshita R, Watanabe M, Huang P, et al. The cysteine-rich core domain of REIC/Dkk-3 is critical for its effect on monocyte differentiation and tumor regression[J]. Oncol Rep, 2015,33(6):2908-2914. doi: 10.3892/or.2015.3885. doi: 10.3892/or.2015.3885 pmid: 25823913
[12]	Yang L, Zhao S, Xia P, et al. Down-regulated REIC expression in lung carcinogenesis: a molecular target for gene therapy[J]. Histol Histopathol, 2018,33(7):691-704. doi: 10.14670/HH-11-964. doi: 10.14670/HH-11-964 pmid: 29341059
[13]	Hamzehzadeh L, Caraglia M, Atkin SL, et al. Dickkopf homolog 3 (DKK3): A candidate for detection and treatment of cancers?[J]. J Cell Physiol, 2018,233(6):4595-4605. doi: 10.1002/jcp.26313. doi: 10.1002/jcp.26313 pmid: 29206297
[14]	刘礼, 袁昌劲, 郭敬杰, 等. 5-氮杂胞苷对DKK3去甲基化及对SGC7901胃癌细胞增殖的影响[J]. 实用预防医学, 2018,25(2):160-161,248. doi: 10.3969/j.issn.1006-3110.2018.02.009. doi: 10.3969/j.issn.1006-3110.2018.02.009
[15]	Zhou Z, Li HQ, Liu F. DNA Methyltransferase Inhibitors and their Therapeutic Potential[J]. Curr Top Med Chem, 2018,18(28):2448-2457. doi: 10.2174/1568026619666181120150122. doi: 10.2174/1568026619666181120150122
[16]	Sawahara H, Shiraha H, Uchida D, et al. Promising therapeutic efficacy of a novel reduced expression in immortalized cells/dickkopf-3 expressing adenoviral vector for hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2017,32(10):1769-1777. doi: 10.1111/jgh.13757. doi: 10.1111/jgh.13757
[17]	Oyama A, Shiraha H, Uchida D, et al. A Phase I/Ib trial of Ad-REIC in liver cancer: study protocol[J]. Future Oncol, 2019,15(31):3547-3554. doi: 10.2217/fon-2019-0115. doi: 10.2217/fon-2019-0115
[18]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. doi: 10.3322/caac.21492. doi: 10.3322/caac.21492
[19]	Cohen PA, Jhingran A, Oaknin A, et al. Cervical cancer[J]. Lancet, 2019,393(10167):169-182. doi: 10.1016/S0140-6736(18)32470-X. doi: S0140-6736(18)32470-X pmid: 30638582
[20]	Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis[J]. Lancet Glob Health, 2020,8(2):e191-e203. doi: 10.1016/S2214-109X(19)30482-6. doi: 10.1016/S2214-109X(19)30482-6
[21]	Lee EJ, Jo M, Rho SB, et al. Dkk3, downregulated in cervical cancer, functions as a negative regulator of beta-catenin[J]. Int J Cancer, 2009,124(2):287-297. doi: 10.1002/ijc.23913. doi: 10.1002/ijc.23913
[22]	Ryu SW, Kim JH, Kim MK, et al. Reduced expression of DKK3 is associated with adverse clinical outcomes of uterine cervical squamous cell carcinoma[J]. Int J Gynecol Cancer, 2013,23(1):134-140. doi: 10.1097/IGC.0b013e3182754feb. doi: 10.1097/IGC.0b013e3182754feb
[23]	Luo S, Li N, Yu S, et al. MicroRNA-92a promotes cell viability and invasion in cervical cancer via directly targeting Dickkopf-related protein 3[J]. Exp Ther Med, 2017,14(2):1227-1234. doi: 10.3892/etm.2017.4586. doi: 10.3892/etm.2017.4586
[24]	毕春燕, 王保莲, 王文翔, 等. DKK3下调IL-32β对宫颈癌细胞增殖、凋亡、迁移、侵袭的影响[J]. 中国老年学杂志, 2020,40(23):5052-5057. doi: 10.3969/j.issn.1005-9202.2020.23.035. doi: 10.3969/j.issn.1005-9202.2020.23.035
[25]	Jiang T, Huang L, Wang S, et al. Clinical significance of serum Dkk-3 in patients with gynecological cancer[J]. J Obstet Gynaecol Res, 2010,36(4):769-773. doi: 10.1111/j.1447-0756.2010.01234.x. doi: 10.1111/j.1447-0756.2010.01234.x
[26]	van der Meide WF, Snellenberg S, Meijer CJ, et al. Promoter methylation analysis of WNT/β-catenin signaling pathway regulators to detect adenocarcinoma or its precursor lesion of the cervix[J]. Gynecol Oncol, 2011,123(1):116-122. doi: 10.1016/j.ygyno.2011.06.015. doi: 10.1016/j.ygyno.2011.06.015 pmid: 21726894
[27]	Zhang M, Huang M, Cao B, et al. Methylation of the DKK3 promoter is associated with poor prognosis in patients with cervical adenocarcinoma[J]. Int J Clin Exp Pathol, 2018,11(2):788-794.
[28]	Kang WS, Cho SB, Park JS, et al. Clinico-epigenetic combination including quantitative methylation value of DKK3 augments survival prediction of the patient with cervical cancer[J]. J Cancer Res Clin Oncol, 2013,139(1):97-106. doi: 10.1007/s00432-012-1262-7. doi: 10.1007/s00432-012-1262-7